Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 36 | 2020 | 800 | 2.100 |
Why?
|
| Oligodendroglioma | 15 | 2017 | 45 | 1.330 |
Why?
|
| Glioblastoma | 10 | 2020 | 274 | 0.760 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2020 | 1398 | 0.430 |
Why?
|
| Dacarbazine | 6 | 2017 | 101 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2020 | 2556 | 0.360 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 134 | 0.350 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2013 | 296 | 0.330 |
Why?
|
| Drug Therapy | 2 | 2009 | 70 | 0.320 |
Why?
|
| Evidence-Based Medicine | 8 | 2009 | 446 | 0.280 |
Why?
|
| Bevacizumab | 8 | 2020 | 270 | 0.280 |
Why?
|
| Astrocytoma | 4 | 2008 | 86 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 6 | 2011 | 1399 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 1 | 4 | 2014 | 101 | 0.240 |
Why?
|
| Glioma | 2 | 2005 | 303 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 6 | 2009 | 1079 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2009 | 304 | 0.210 |
Why?
|
| Combined Modality Therapy | 12 | 2011 | 1733 | 0.210 |
Why?
|
| Salvage Therapy | 4 | 2010 | 234 | 0.200 |
Why?
|
| Antineoplastic Agents | 6 | 2017 | 2368 | 0.190 |
Why?
|
| Parkinson Disease | 3 | 1990 | 157 | 0.190 |
Why?
|
| Survival Rate | 13 | 2014 | 1927 | 0.180 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2017 | 90 | 0.180 |
Why?
|
| La Crosse virus | 1 | 2000 | 2 | 0.180 |
Why?
|
| Encephalitis, California | 1 | 2000 | 2 | 0.180 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2000 | 16 | 0.170 |
Why?
|
| Radiotherapy | 4 | 2016 | 324 | 0.170 |
Why?
|
| Carmustine | 3 | 2017 | 70 | 0.160 |
Why?
|
| Decanoic Acids | 1 | 2017 | 11 | 0.150 |
Why?
|
| Adult | 26 | 2020 | 27532 | 0.140 |
Why?
|
| Polyesters | 1 | 2017 | 42 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2013 | 977 | 0.140 |
Why?
|
| Middle Aged | 26 | 2017 | 27030 | 0.130 |
Why?
|
| Humans | 43 | 2020 | 92337 | 0.130 |
Why?
|
| Levodopa | 2 | 1987 | 38 | 0.130 |
Why?
|
| Treatment Outcome | 15 | 2016 | 8740 | 0.130 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 88 | 0.120 |
Why?
|
| Procarbazine | 6 | 2011 | 38 | 0.120 |
Why?
|
| Lomustine | 6 | 2011 | 26 | 0.120 |
Why?
|
| Vincristine | 6 | 2011 | 109 | 0.120 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 1181 | 0.120 |
Why?
|
| Decision Trees | 1 | 2014 | 62 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2006 | 923 | 0.110 |
Why?
|
| Chemoradiotherapy | 2 | 2017 | 318 | 0.110 |
Why?
|
| Male | 26 | 2017 | 43925 | 0.110 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 230 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 165 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2013 | 294 | 0.100 |
Why?
|
| Aged | 17 | 2017 | 19943 | 0.100 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 3775 | 0.100 |
Why?
|
| Meningeal Neoplasms | 2 | 2008 | 71 | 0.100 |
Why?
|
| Thiotepa | 4 | 2008 | 32 | 0.100 |
Why?
|
| Female | 25 | 2017 | 47893 | 0.100 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 174 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 233 | 0.090 |
Why?
|
| Movement Disorders | 1 | 1990 | 43 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 1990 | 76 | 0.080 |
Why?
|
| Whole-Body Irradiation | 1 | 2009 | 68 | 0.080 |
Why?
|
| Radiosurgery | 2 | 2009 | 297 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2011 | 240 | 0.080 |
Why?
|
| Brain Ischemia | 1 | 2013 | 405 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 278 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2011 | 3509 | 0.080 |
Why?
|
| Steroids | 1 | 2009 | 173 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 162 | 0.080 |
Why?
|
| Meninges | 1 | 2008 | 14 | 0.070 |
Why?
|
| Young Adult | 7 | 2016 | 6624 | 0.070 |
Why?
|
| Prognosis | 6 | 2016 | 3872 | 0.070 |
Why?
|
| Neurosurgery | 1 | 2009 | 123 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 66 | 0.070 |
Why?
|
| MMPI | 1 | 1987 | 10 | 0.070 |
Why?
|
| Seizures | 1 | 2009 | 312 | 0.070 |
Why?
|
| Disease Progression | 5 | 2011 | 1503 | 0.070 |
Why?
|
| Hallucinations | 1 | 1987 | 30 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2007 | 90 | 0.070 |
Why?
|
| Cognition | 1 | 2011 | 603 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2008 | 1511 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2009 | 443 | 0.060 |
Why?
|
| Carbidopa | 1 | 1986 | 5 | 0.060 |
Why?
|
| Dystonia | 1 | 1986 | 30 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 34 | 0.060 |
Why?
|
| Cranial Irradiation | 3 | 2009 | 41 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 866 | 0.060 |
Why?
|
| Adolescent | 7 | 2014 | 9504 | 0.060 |
Why?
|
| Stroke | 1 | 2013 | 1038 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 6916 | 0.050 |
Why?
|
| DNA Modification Methylases | 2 | 2016 | 29 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2017 | 4468 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2014 | 9703 | 0.050 |
Why?
|
| International Agencies | 2 | 2012 | 34 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 619 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2003 | 268 | 0.050 |
Why?
|
| Transplantation, Autologous | 2 | 2017 | 355 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2000 | 43 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2012 | 60 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2000 | 145 | 0.040 |
Why?
|
| Iodine Radioisotopes | 2 | 1998 | 135 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 389 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 410 | 0.040 |
Why?
|
| Tenascin | 1 | 1998 | 9 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 1999 | 172 | 0.040 |
Why?
|
| Karnofsky Performance Status | 3 | 2008 | 41 | 0.040 |
Why?
|
| Drug Implants | 1 | 2017 | 36 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2016 | 677 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 57 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 485 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 2035 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 190 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1592 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 1996 | 27 | 0.030 |
Why?
|
| Brain | 3 | 2008 | 2352 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 887 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2009 | 955 | 0.030 |
Why?
|
| Alleles | 1 | 1999 | 1141 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2012 | 475 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 1999 | 456 | 0.030 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 55 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 37 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 600 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1999 | 1150 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 416 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 902 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2015 | 498 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1016 | 0.020 |
Why?
|
| Etoposide | 2 | 2003 | 206 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2013 | 251 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 351 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1999 | 2680 | 0.020 |
Why?
|
| MEDLINE | 1 | 2009 | 8 | 0.020 |
Why?
|
| Metalloporphyrins | 1 | 2009 | 26 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 82 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2009 | 98 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1576 | 0.020 |
Why?
|
| Biological Transport | 1 | 1990 | 410 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 523 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 498 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 86 | 0.020 |
Why?
|
| Camptothecin | 1 | 2009 | 198 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2008 | 56 | 0.020 |
Why?
|
| Cerebellopontine Angle | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cerebrum | 1 | 2008 | 15 | 0.020 |
Why?
|
| Busulfan | 1 | 2008 | 41 | 0.020 |
Why?
|
| Time | 1 | 2008 | 79 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 868 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 293 | 0.020 |
Why?
|
| Meige Syndrome | 1 | 1986 | 1 | 0.020 |
Why?
|
| Pergolide | 1 | 1986 | 3 | 0.020 |
Why?
|
| Ergolines | 1 | 1986 | 8 | 0.020 |
Why?
|
| Bromocriptine | 1 | 1986 | 12 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 569 | 0.020 |
Why?
|
| Torticollis | 1 | 1986 | 11 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 379 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 968 | 0.020 |
Why?
|
| Risk | 1 | 1987 | 661 | 0.010 |
Why?
|
| Psychometrics | 1 | 1987 | 335 | 0.010 |
Why?
|
| United States | 1 | 2017 | 7348 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 312 | 0.010 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1984 | 22 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1984 | 40 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 2978 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1984 | 96 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 1956 | 0.010 |
Why?
|
| Melphalan | 1 | 2003 | 100 | 0.010 |
Why?
|
| Methotrexate | 1 | 2003 | 245 | 0.010 |
Why?
|
| Cytarabine | 1 | 2003 | 222 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 145 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1720 | 0.010 |
Why?
|
| Remission Induction | 1 | 2003 | 763 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1984 | 264 | 0.010 |
Why?
|
| Cachexia | 1 | 2000 | 13 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 2000 | 40 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 289 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 289 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2000 | 186 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1998 | 21 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1998 | 102 | 0.010 |
Why?
|
| Immunoassay | 1 | 1998 | 93 | 0.010 |
Why?
|
| Cisplatin | 1 | 2000 | 602 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1998 | 159 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2000 | 360 | 0.010 |
Why?
|
| Mitomycin | 1 | 1996 | 29 | 0.010 |
Why?
|
| Mercaptopurine | 1 | 1996 | 53 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1996 | 226 | 0.010 |
Why?
|
| Biopsy | 1 | 1998 | 1194 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1998 | 725 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1996 | 3818 | 0.000 |
Why?
|
| Child | 1 | 1998 | 7334 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 311 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1984 | 171 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1984 | 302 | 0.000 |
Why?
|
| Perfusion | 1 | 1984 | 261 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1984 | 997 | 0.000 |
Why?
|
| Mice | 1 | 1996 | 12110 | 0.000 |
Why?
|
| Thyroxine | 1 | 1984 | 376 | 0.000 |
Why?
|
| Animals | 2 | 1996 | 28003 | 0.000 |
Why?
|
| Time Factors | 1 | 1990 | 5430 | 0.000 |
Why?
|
| Kinetics | 1 | 1984 | 1550 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1984 | 2902 | 0.000 |
Why?
|
| Rats | 1 | 1984 | 4067 | 0.000 |
Why?
|